Business Context and Reporting Period
Company: Salarius Pharmaceuticals, Inc. (Note: Request metadata referenced Decoy Therapeutics, but the filing text identifies Salarius Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date: December 12, 2024
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) with C/M Capital Master Fund, LP.
Key Financial Metrics and Capital Structure
This filing describes a potential equity financing arrangement rather than reporting historical financial performance. Key terms include:
- Maximum Potential Proceeds: Up to $10 million in newly issued common stock (Purchase Shares).
- Commitment Shares: The Company will issue 1% of the number of Purchase Shares sold as additional shares to the Purchaser as consideration for the agreement.
- Exchange Cap: Issuance is limited to 19.99% of the total shares outstanding immediately preceding the agreement, unless shareholder approval is obtained or specific pricing thresholds are met.
- Beneficial Ownership Limitation: The Purchaser is not obligated to buy shares if it would result in beneficial ownership exceeding 4.99% (waivable up to 9.99% with notice).
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing does not provide current revenue, profit, cash flow, or debt figures.
Material Changes and Transaction Mechanics
The Company has entered into a "fixed purchase" and "VWAP purchase" facility with the following mechanics:
- Duration: 36 months from the Commencement Date (when the registration statement is declared effective).
- Trigger Price: Sales can only occur on days when the previous day's closing price is at least $1.00.
- Pricing: Purchase price is generally 95% of the lesser of the VWAP or the closing price, subject to a "New Issuance Price" adjustment if the Company issues securities at a lower price subsequently.
- Daily Limits: Fixed purchases are capped at $200,000 per day. Combined VWAP and Additional VWAP purchases are capped at $2.5 million per day unless waived.
- Termination: The Company may terminate the agreement at any time with one business day's notice at no cost.
Guidance, Risks, and Contingencies
- Registration Requirement: The Company must file a Form S-1 registration statement within 30 days and have it declared effective by the SEC before any sales can commence.
- Market Conditions: Actual sales depend on market conditions and the Company's determination of funding needs; the Purchaser has no right to require sales.
- Dilution Risk: The issuance of Commitment Shares and Purchase Shares will dilute existing shareholders, subject to the 19.99% Exchange Cap.
- Price Adjustment Risk: If the Company issues securities at a price lower than the purchase price paid by the Purchaser, the purchase price for future sales under this agreement may be reduced.
Investor Verification Checklist
- Verify the effectiveness of the Form S-1 registration statement required to commence sales.
- Monitor the Company's stock price to ensure it remains above the $1.00 threshold required for purchases.
- Review the Company's capitalization table to assess the impact of the 19.99% Exchange Cap and potential dilution from Commitment Shares.
- Check for any subsequent issuances of securities at prices lower than the current market price, which could trigger price adjustments under the agreement.
- Confirm the Company's current cash position and burn rate to determine the likelihood of utilizing the full $10 million facility.